Innate Pharma S.A. Sponsored ADR IPHA
1.70
0.00
0.00%
as of 25 Sep
- Market cap
- $188.8M
- P/E
- 0.0×
Follow IPHA
| Older periods | Dec '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
0.00% | 0.00% | 0.00% | 0.00% | |
| 0.00% | 0.00% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(53.21) | (75.82) | (100.21) | (127.75) | |
Capital Expenditures |
(1.28) | (1.01) | (0.95) | (0.75) | |
| Other line items | |||||
Cash ROIC |
(39.79%) | (71.47%) | (249.38%) | 1,161.21% | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | — | 0.00% | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.00 | 1.72 | 0.00 | 1.24 | |
Capex/Depreciation |
(0.10) | (0.10) | (0.17) | (0.14) | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates